A regularized functional regression model enabling transcriptome-wide dosage-dependent association study of cancer drug response by Koukouli, E. et al.
This is a repository copy of A regularized functional regression model enabling 
transcriptome-wide dosage-dependent association study of cancer drug response.




Koukouli, E., Wang, D. orcid.org/0000-0003-0068-1005, Dondelinger, F. et al. (1 more 
author) (2021) A regularized functional regression model enabling transcriptome-wide 
dosage-dependent association study of cancer drug response. PLOS Computational 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
A regularized functional regressionmodel
enabling transcriptome-wide dosage-
dependent association study of cancer drug
response
Evanthia KoukouliID
1*, DennisWangID2,3, Frank DondelingerID4☯, Juhyun ParkID1☯
1Department of Mathematics and Statistics, Fylde College, Lancaster University, Bailrigg, Lancaster, UK,
2 Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK, 3Department of
Computer Science, University of Sheffield, Sheffield, UK, 4Centre for Health Informatics and Statistics,
Lancaster Medical School, Lancaster University, Bailrigg, Lancaster, UK
☯ These authors contributed equally to this work.
* e.koukouli@lancaster.ac.uk
Abstract
Cancer treatments can be highly toxic and frequently only a subset of the patient population
will benefit from a given treatment. Tumour genetic makeup plays an important role in can-
cer drug sensitivity. We suspect that gene expression markers could be used as a decision
aid for treatment selection or dosage tuning. Using in vitro cancer cell line dose-response
and gene expression data from the Genomics of Drug Sensitivity in Cancer (GDSC) project,
we build a dose-varying regression model. Unlike existing approaches, this allows us to esti-
mate dosage-dependent associations with gene expression. We include the transcriptomic
profiles as dose-invariant covariates into the regression model and assume that their effect
varies smoothly over the dosage levels. A two-stage variable selection algorithm (variable
screening followed by penalized regression) is used to identify genetic factors that are asso-
ciated with drug response over the varying dosages. We evaluate the effectiveness of our
method using simulation studies focusing on the choice of tuning parameters and cross-vali-
dation for predictive accuracy assessment. We further apply the model to data from five
BRAF targeted compounds applied to different cancer cell lines under different dosage lev-
els. We highlight the dosage-dependent dynamics of the associations between the selected
genes and drug response, and we perform pathway enrichment analysis to show that the
selected genes play an important role in pathways related to tumorigenesis and DNA dam-
age response.
Author summary
Tumour cell lines allow scientists to test anticancer drugs in a laboratory environment.
Cells are exposed to the drug in increasing concentrations, and the drug response, or
amount of surviving cells, is measured. Generally, drug response is summarized via a sin-
gle number such as the concentration at which 50% of the cells have died (IC50). To avoid
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relying on such summary measures, we adopted a functional regression approach that
takes the dose-response curves as inputs, and uses them to find biomarkers of drug
response. One major advantage of our approach is that it describes how the effect of a bio-
marker on the drug response changes with the drug dosage. This is useful for determining
optimal treatment dosages and predicting drug response curves for unseen drug-cell line
combinations. Our method scales to large numbers of biomarkers by using regularization
and, in contrast with existing literature, selects the most informative genes by accounting
for drug response at untested dosages. We demonstrate its value using data from the
Genomics of Drug Sensitivity in Cancer project to identify genes whose expression is asso-
ciated with drug response. We show that the selected genes recapitulate prior biological
knowledge, and belong to known cancer pathways.
This is a PLOS Computational BiologyMethods paper.
Introduction
Cancer is a heterogeneous disease, with individual tumours showing sometimes very different
mutational and molecular profiles. The genetic makeup of a tumour influences how it reacts
to a given anti-cancer drug. However, due to lack of predictive markers of tumour response,
often patients with very different tumour genetic makeup will receive the same therapy, result-
ing in high rates of treatment failure [1]. Large clinical trials in rapidly lethal diseases are
expensive, complex and often lead to failure due to lack of efficacy at a given dosage [2]. One
major issue for some cancer treatments, e.g. chemotherapies, are cytotoxic effects that result in
collateral damage of the healthy host tissue [3]. Patient remission depends not only on the
selection of the right drug but also on the determination of the optimal dosage, especially
when drugs with small therapeutic range, high toxicity levels or both are administered. Genetic
factors can help fine-tune the dosage for individual patients, so that the minimal effective dos-
age can be delivered [4].
Treatment response in patients with specific cancers had been intensely examined in rela-
tion to the molecular characteristics of the tumours [5]. However, cellular heterogeneity within
the tumour and the lack of standard metrics for quantifying drug response in patients can
make it difficult to computationally model response as a function of molecular features. Can-
cer cell line drug screens can provide valuable information about the effect of genetic features
on drug dose-response in a controlled setting. During the last decade, there have been several
systematic studies that examined the relationship between genetic variants and drug response
in cell lines [6–10]. There have also been studies that measured transcriptional profiles [11, 12]
and drug response in cancer cells after administering anticancer drugs at various dosages [13,
14]. By comparing multiple genomic features of cell lines to drug response, the investigators
were able to identify gene signatures for drug responsiveness in specific cancer types. However,
these signatures were selected based on a single summary statistic of response, usually IC50,
that may not always be the most useful metric for differentiating drugs [15], and only provides
information on one dose concentration. While these existing signatures of drug response pro-
vide a way towards selecting the right drug for a patient, none of them characterize gene-dose
relationships that may ultimately identify the optimal dose for a drug to use in the clinic.
With regards to the high-dimensional nature of genomic data sets, it is worth noting that
highly-complex data sets with non-stationary trends are not easily amenable to analysis by
classic parametric or semi-parametric mixed models. Such effects, e.g. the effect of genes on
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drug response over different drug dosages (dose-varying effect), can be examined using vary-
ing coefficient models which allow for the covariate effect to be varying instead of constant
[16]. Methods to estimate varying covariate effects include global and local smoothing, e.g.
kernel estimators [17, 18], basis approximation [19] or penalized splines [20]. Although non-
parametric techniques can reduce modeling biases [21], they often suffer from the “curse of
dimensionality” [22]. Inference in these models becomes impossible as the number of predic-
tors increases, and often selecting a smaller number of important variables for inclusion into
the model is clinically beneficial. Sparse regression has enabled a more flexible and computa-
tionally “inexpensive” way of choosing the best subset of predictors [23]. However, these meth-
ods cannot handle ultra-high dimensional problems without losing statistical accuracy and
algorithmic stability, since they handle all of the predictors jointly. Consequently, there is a
need of prior univariate tests focused on filtering out the unimportant predictors by estimating
the association of each predictor to the outcome variable separately [21, 24, 25]. The advantage
of using varying coefficient models along with a variable screening algorithm on genomic data
sets was first introduced to explore the effect of genetic mutations on lung function [24].
Recently, Wang et al. [26] and Tansey et al. [27] independently proposed methods for model-
ing drug-response curves via Gaussian processes and linking them to biomarkers. In both
cases, the authors did not use their models for dosage-dependent inference of biomarker
effects. Additionally, the highly non-linear neural network model in Tansey et al. [27] makes
interpretation of biomarker effects challenging.
Here, we extended the methodology of Chu et al. [24] to the objective of assessing the tran-
scriptomic effect on anti-cancer drug response, where our coefficient functions were allowed
to vary with dosage. We developed a functional regression framework to study the effective-
ness of multiple anticancer agents applied in different cancer cell lines under different dosage
levels, adjusting for the transcriptomic profiles of the cell lines under treatment. We consid-
ered a dose-varying coefficient model, along with a two-stage variable selection method in
order to detect and evaluate drug-gene relationships, and then applied this method to data
extracted from the Genomics for Drug Sensitivity in Cancer (GDSC) project [7]. To compare
and differentiate similar treatments, we examined a case study of five BRAF targeted com-
pounds under different dosages to almost 1000 cancer cell lines. We used baseline gene expres-
sion measurements for the cancer cell lines to investigate gene-drug response relationships for
almost 18000 genes. Gene rankings were obtained based on the estimated effects of the genes
on the drug response. The resulting model describes the whole dose-response curve, rather
than a summary statistic of drug response (e.g. IC50), which allowed us to identify trends in
the gene-drug association at untested dose concentrations.
Materials andmethods
The Genomics of drug sensitivity in cancer data
Drug sensitivity data and molecular measures derived from 951 cancer cell lines used for the
screening of 138 anticancer compounds were downloaded from the GDSC database (https://
www.cancerrxgene.org/). We specifically focused on cell lines of cancers of epithelial, mesen-
chymal and haematopoietic origin treated by five BRAF targeted inhibitors (PLX-4720,
Dabrafenib, HG6-64-1, SB590885 and AZ628; GDSC1 data). The maximum screening con-
centration for each different drug was: 10.00 uM for PLX-4720 and Dabrafenib, 5.12 uM for
HG6-64-1, 5.00 uM for SB590885 and 4.00 uM for AZ628. Additionally, we used the indepen-
dently generated GDSC2 data set to validate our approach on drugs targetingMEK1,MEK2
genes (Trametinib−1.00 uM; Selumetinib−10.00 uM, and; PD0325901−0.250 uM) and the
PI3K/MTOR signalling pathway (Alpelisib−10.00 uM; AMG-319−10.00 uM, and; AZD8186
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−10.00 uM). The drug sensitivity measurement was obtained via fluorescence-based cell viabil-
ity assays 72 hours after drug administration [7]. Approximately 66% of drug sensitivity
responses were measured over nine dose concentrations (2-fold dilutions) and 34% were mea-
sured over five drug concentrations (4-fold dilutions). In total, we considered 3805 cancer cell
line-drug combinations (experimental units). The distribution of different tissues of origin
treated were similar across the different drugs tested (for additional information see S1 Fig).
Paired microarray gene expression data (17737 genes) were available together with the dose-
response data.
The dose-response data also included a blank response for cells on the experimental plate
that had not been seeded with cells or treated with a drug. Blank responses have been used to
adjust for the magnitude of the observation error while measuring the amount of cells in each
plate. We used an affine transformation to the reported responses in order to normalise them
within the drug concentration interval, 0 (0% of the maximum dosage) to 1 (100% of the maxi-





where Rij is the response of the ith experimental unit at the jth dosage level, CRi is the response
under no drug administration (zero dose, ni = 1), BRi is the blank response of the ith experi-
mental unit as described above and NRij is the new score taken from the transformation, i = 1,
. . ., 3805, j = 1, . . ., ni.
A two-stage algorithm for identification of gene-drug associations
Non-parametric techniques are a great tool for reducing modeling bias and producing data
driven inference. However, flexible modeling techniques applied on high-dimensional geno-
mic data sets can often cause real problems in statistical inference. Sparse regression tech-
niques, such as the LASSO, can be used as dimensionality reduction techniques, but cannot
handle ultra-high dimensional problems without introducing statistical inaccuracies, algorith-
mic instability and a huge computational burden [23]. Hence, the need for a feature screening
algorithm which will marginally filter unimportant variables becomes essential. Below we fur-
ther explain the two-stage algorithm that has been built in order to detect and explore dose-
dependent gene-response associations.
Let the repeated measures data {(dij, yij, zi, xi):j = 1, . . ., ni, i = 1, . . ., n}, where yij is the
response of the ith experimental unit (corresponds to a drug sensitivity assay of a specific drug
on a specific cell line) at the jth drug dosage level dij and zi along with xi are the corresponding
vectors of scalar (dose-invariant) covariates. The covariate vector zi = (1, zi1, . . ., zip)
T is a low-
dimensional vector of predictors that should be included in the model, whereas xi = (xi1, xi2,
. . ., xiG)
T is a high-dimensional vector, i.e. 17737 gene expression measurements, that needs
to be screened. We assumed that only a small number of x-variables (in our case, genes) are
truly associated with the response while most of them are expected to be irrelevant (sparsity
assumption).
To explore potential dose-varying effects between the covariates and the drug response, we







xigggðdijÞ þ εij ð2Þ
where {βk(�), k = 0, . . ., p} and {γg(�), g = 1, . . ., G} are smooth functions of dosage level d 2 D ,
whereD is a closed and bounded interval of R. The errors εij were assumed to be independent
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across subjects and potentially dependent within the same subject with conditional mean
equal to zero and variance Var(ε) = σ2(d) = V(d).
Methods for estimating the coefficient functions in Eq (2) include local and global smooth-
ing methods, such as kernel smoothing, local polynomial smoothing, basis approximation
smoothing etc. For computational convenience, in this application we used basis approxima-
tion smoothing via B-splines.
Let the sets of basis functions {Blk(�):l = 1, . . ., Lk} and fB
0
lgð�Þ : l ¼ 1; . . . ; Lgg and constants
{zlk: l = 1, . . ., Lk} and {ηlg: l = 1, . . ., Lg} where k = 0, . . ., p and g = 1, . . ., G such that, 8d 2 D ,










lgð�Þ for g ¼ 1; . . . ;G: ð4Þ















lgðdijÞ þ εij ð5Þ
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< . . . < dKk < dKkþ1 and d0 < d1 < . . . < dKg < dKgþ1 are the corresponding knots,
then Lk = Kk + qk and Lg = Kg + qg.
Using the approximation Eq (5), the coefficients ζ = (z0, z1, . . ., zp)
T and η = (η1, η2, . . ., ηG)
T

























where wij are known non-negative weights.
In cases where p + G>>n though, minimisation of Eq (6) is infeasible. Our aim was to
identify factors of the covariate vector x = (x1, x2, . . ., xG)
T (genes) that are truly associated
with the response (cancer cell line sensitivity to the drug). In addition, we wanted to explore
potential dose-varying effects on the drug response.
We make the following sparsity assumption: any valid solution γ̂ðdÞ will have ĝg ðdÞ ¼
0;8d 2 D for the majority of components g. To detect non-zero coefficient functions, we
applied a two-stage approach which incorporated a variable screening step and a further vari-
able selection step.
Screening. The sparsity assumption applies only to components of x, the high-dimen-
sional covariate vector in Eq (2).
Let the set of indices
M
0
¼ f1 � g � G : kggð�Þk2 > 0g ð7Þ
where k�k2 is the L2-norm. In order to rank the different components of x, we fitted the
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where: fBðgÞlk ð�Þ : l ¼ 1; . . . ; Lkg and fB
ðgÞ0
lg ð�Þ : l ¼ 1; . . . ; Lgg are sets of coefficient functions;
fzðgÞlk : l ¼ 1; . . . ; Lkg and fZ
ðgÞ
lg : l ¼ 1; . . . ; Lgg are constants to be estimated, k = 0, . . ., p;
and, ε(g) is the error term similar to Eq (5). We then computed the following weighted mean


























where V̂ i is the ni × ni diagonal matrix consisting of the dose-varying variance
V̂ i ¼
V̂ ðdi1Þ 0 � � � 0



















and Ri(ϕ) = (Rjk) the ni × ni working correlation matrix for the ith subject. By ϕ, we denoted
the s × 1 vector that fully characterizes the correlation structure. The estimate of ϕ, ϕ̂, was
obtained by taking the moment estimators for the parameters ϕ in the correlation structure




zikbkðdijÞ þ εij where i ¼ 1; . . . ; n; j ¼ 1; . . . ; ni: ð12Þ
The variance function V(d) in Eq (11) was estimated using techniques described in [24].
After having obtained {ûg : g ¼ 1; . . . ;G}, we sorted gene utilities in an increasing order,
where smaller ûg values indicate stronger marginal associations. The x-predictors included in
the screened submodel are, then, given by
cM tn ¼ f1 � g � G : ûg ranks among the first tnðnÞg ð13Þ
where τn(ν) corresponds to the size of the submodel which is chosen to be smaller than the
sample size n.
Variable selection using a group SCAD (gSCAD) penalty. Screening algorithms aim to
discard all unimportant variables but tend to be conservative. In order to preserve only the
most important x-predictors in the final model, we considered a model including the first
PLOS COMPUTATIONAL BIOLOGY Biomarker detection for revealing anticancer drug dynamics
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α is a scale parameter, λ controls for the penalty size and k�k is the Euclidean ℓ2-norm. At this
point, note that grouping is applied for the coefficients ηg that correspond to the same coeffi-
cient function. In addition, in order to reduce the bias introduced when applying a LASSO
penalty, we alternatively chose the SCAD, which coincides with the LASSO until u = λ, then
transits to a quadratic function until u = αλ and then it remains constant 8u> αλ, meaning
that it retains the penalization and bias rates of the LASSO for small coefficients but at the
same time relaxes the rate of penalization as the absolute value of the coefficients increases. In
Fig 1 the reader can find a brief overview of the employed methodology.
Tuning parameter selection
We used knots placed at the median of the observed data values along with cubic B-splines





proposed and applied by [19, 28, 29]. Due to the computational burden this
would add, we did not apply cross-validation.




, ν 2 {1, 2, 3, . . .}. We conducted a pilot simulation study in order to decide the most
appropriate size (for further details see S1 Text). We also considered an automated algorithm
for its selection (Greedy Iterative Non-parametric Independence Screening-Greedy INIS,
[21]). Finally, the penalty size for the gSCAD step λ was determined using a 5-fold cross-
validation.
Simulation study
Monte Carlo simulations were conducted to examine the ability of our model to detect the
genes that are truly associated with the drug response. This had a key role in tuning model
parameters and simultaneously assessing model goodness-of-fit using a fraction of the original
data set in order to reduce the computational burden of conducting a simulation study under
the original dimensions of the data. Responses over different dosage levels were generated
based on a subset of genes, the corresponding low-dimensional GDSC data covariates (drug
and cancer type) and some prespecified smooth coefficient functions (see S1 Text). In particu-
lar, we repeatedly sampled without replacement 190 experimental units and 886 genes based
PLOS COMPUTATIONAL BIOLOGY Biomarker detection for revealing anticancer drug dynamics
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Fig 1. The two-stage algorithm for identifying dose-dependent associations between genes and drugs.Gene expression and drug response data from a drug
screening study (e.g. GDSC) are used to fit our dose-varying coefficients model to estimate the dose-varying effect between covariates and drug response. A two-stage
variable screening and selection algorithm is applied to rank gene-drug associations. The selected genes can then be used to predict dose-dependent response for the
drugs of interest.
https://doi.org/10.1371/journal.pcbi.1008066.g001
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on which the simulated responses have been generated. The performance of the employed









and τn(ν) chosen using the greedy-INIS algorithm [21]) and
two estimated covariance structure scenarios (independence and rational quadratic covariance
structure). Cubic B-splines and knots placed at the median of the observed data values have
been used for estimating the coefficient functions.
To evaluate the performance of the proposed procedure we used the following summary
measures: TP−number of genes correctly identified as active; FP−number of the genes incor-
rectly identified as active; TN−number of the genes correctly identified as inactive; FN−num-
ber of the genes incorrectly identified as inactive.
Simulation results suggested that our method accurately detects the drug associated genes
from the simulated responses under most of the examined scenarios (S1 Text). A screening
threshold of size 2n
logðnÞ
h i
and regression weights adjusted for the covariance structure of the
data were identified as the scenario where our method reached its maximum accuracy. Conse-
quently, for the GDSC application, we chose the screening threshold to be the maximum possi-
ble, i.e. 923 genes derived from the formula 2n
logðnÞ
h i
, and weights derived by assuming a rational
quadratic covariance structure for the repeated measures.
Software availability
The analysis has been conducted using R version 3.6.3. Code for applying the two-stage vari-
able selection algorithm is available online as an R package at https://github.com/koukoulEv/
fbioSelect.
Results and discussion
Dose-dependent associations with gene expression in a large-scale drug
sensitivity assay
We applied the two stage variable selection algorithm under the dose-varying coefficient
model framework described above. Gene rankings and predicted mean drug effects over dif-
ferent dosage levels were obtained. Our algorithm identified 230 candidate genes associated
with drug response. The effect of each of those genes was assessed with respect to:
1. the area under the estimated coefficient curve (AUC) and its corresponding standard devia-
tion (estimated using bootstrapping);
2. the effect on cell survival (overall positive, overall negative, mixed);
3. Spearman correlation between the coefficient function value and the dosage level;
4. the mean fold change of the expression of cell lines carrying BRAFmutations with respect
to wild type; and,
5. the protein-protein interaction network distance between the BRAF gene and the selected
genes using the Omnipath database [30].
The 230 genes were ranked based on the estimated AUC value (S1 Table), and the top 30
genes were highlighted for further analysis (Table 1). The higher the AUC, the larger the effect
of the gene on the drug response. The overall effect on cell survival can be either positive, nega-
tive or vary over the different dosage levels as determined by the range of the estimated
PLOS COMPUTATIONAL BIOLOGY Biomarker detection for revealing anticancer drug dynamics
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coefficient function. Spearman’s rank correlation was used as an indicator of the coefficient
function’s monotonicity by characterising the progress of the genetic effect over different dos-
age levels. For instance, high expression of the C3orf58 gene at baseline has a positive effect
on cancer cell survival, which becomes stronger as the dosage increases (Spearman correla-
tion = 0.922). In other words, high expression of this gene can be an indicator of drug resistant
cell lines. On the other hand, the DLC1 gene has an overall decreasing and negative effect on
cancer cell survival (Spearman correlation = -0.928) which suggested that as the dosage
Table 1. Top 30 gene rankings based on the estimated area under the coefficient function curve.
Gene
Name
Area SD Sign Spearman’s
Correlation
Mean fold change in BRAFmutant vs wild-type
cell lines
Protein-protein interaction network distance to
BRAF
KIR3DL1 0.370 0.107 - -0.874 0.978 3
CHST11 0.257 0.092 - -0.817 0.899 NI
APOC1P1 0.247 0.09 - -0.918 1.190 NI
PLEKHA6 0.239 0.086 - -0.908 1.037 3
PPM1F 0.223 0.068 + 0.910 0.883 3
BFSP1 0.222 0.074 - -0.800 1.217 NI
PPP1R3A 0.217 0.082 + 0.774 1.078 3
C16orf87 0.207 0.087 + 0.851 0.977 NI
PARVA 0.203 0.081 + 0.890 0.984 2
SLC39A13 0.202 0.079 - -0.461 1.055 NI
UCN2 0.198 0.07 - -0.928 0.979 NI
STMN3 0.198 0.087 + 0.834 1.201 2
RNF130 0.197 0.083 - -0.927 1.153 NI
C3orf58 0.196 0.076 + 0.922 1.133 NI
CXXC4 0.188 0.079 + 0.866 0.995 NI
THBD 0.179 0.093 0 -0.967 1.231 4
SIRT3 0.173 0.066 - -0.760 1.013 3
PLAT 0.172 0.092 - -0.878 1.322 4
MPPED1 0.168 0.066 + 0.430 0.978 NI
INSL3 0.162 0.068 - -0.973 0.965 NI
FAM163A 0.159 0.078 - -0.983 1.106 NI
CNIH3 0.153 0.08 - -0.918 0.938 NI
GJA3 0.153 0.067 0 -0.940 0.933 NI
BTG2 0.152 0.078 + 0.959 1.035 2
DLX6 0.152 0.059 0 0.686 0.987 NI
DLC1 0.151 0.053 - -0.928 0.974 3
GAPDHS 0.150 0.077 + 0.886 1.232 NI
JAG2 0.149 0.069 - -0.994 0.981 3
SMOX 0.146 0.057 0 0.816 1.070 NI
ZMYND8 0.145 0.091 + 0.907 1.020 3
Gene rankings of the top 30 selected genes based on the magnitude of the genetic effect on drug response. A positive (+) sign translates to a positive effect on cell
survival after drug administration, a negative (-) sign translates to a negative effect on cell survival and a mixed (0) effect translates to a varying effect on cell survival
which depends on drug dosage. Spearman correlation is calculated between drug dosage and gene estimated coefficient function values as an indicator of the magnitude
change of the gene effect over the increasing dosage. Area corresponds to the area under the estimated coefficient curve and the SD corresponds to the standard
deviation of the area based on bootstrapping. Mean fold change is calculated between the selected gene expression values of the cell lines carrying BRAFmutations with
respect to wild type. Protein-protein interaction network distance is computed based on the shortest interaction path between the BRAF gene and each of the selected
genes. Here, NI denotes absence of any interaction.
https://doi.org/10.1371/journal.pcbi.1008066.t001
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increases, higher baseline expression of this gene can indicate higher drug sensitivity at higher
dosage. Elevated expression of DLC1 has been observed in melanoma and is a well known
tumour suppressor that could be a novel marker of BRAF inhibition [31]. Finally, in cases
where the overall effect varies (changes between positive and negative), the effect of gene
expression on the drug response depends on the drug dosage. In particular, the effect of DLX6
increases and then decreases at higher dosages (Fig 2). Given the biological and technical varia-
tion in drug screens, we should treat the mean effect estimates with caution and consider the
confidence intervals of the coefficient functions in order to derive conclusions about the exact
effect of the selected genes on the dose response (Fig 2).
Coefficient function estimates provide a lot of information about the dosage, cancer type
and genetic effects on drug response. Fig 2 illustrates the estimated coefficient functions for
different drugs, cancer types and three genes in relation to the model intercept, Dabrafenib
response in BRAFmutant cell lines originating from the skin (melanoma). Except from HG6-
64-1, all other BRAF inhibitors (AZ628, SB590885 and PLX4720) showed no additional effect
compared to the intercept. Similar patterns can be observed for cancer cell lines coming from
most of the tissues examined. This result indicates that the examined drugs may have similar
or worse behaviour over the different dosages for most of the examined cancer types. We
observed greater efficacy (negative values of the coefficient function) for cell lines originating
from the endocrine system, autonomic ganglia and heamatopoietic and lymphoid tissues at
lower dosages. The observed effect in endocrine system cell lines reflects the Dabrafenib
responses observed in anaplastic thyroid cancer patients [32]. Interestingly, the drug Trameti-
nib, taken in combination with Dabrafenib is a MEK inhibitor, and genes interacting with
MEK (MAP2K1) were selected features from our model (Fig 3A). Together these results pro-
vide important insights into the effectiveness of the five BRAF targeted drugs examined on dif-
ferent cancer types, highlighting the potential for effective treatment of a wide range of cancers
given the tumour genetic characteristics.
Since the BRAF gene is the target of the drugs, mean fold change and protein-protein inter-
action network distance were used to examine whether and how the selected genes are related
to the target of the inhibition. From the selected genes, 120 genes had a mean fold change
greater than 1 whereas the rest had a mean fold change between 1 and 0.792. Some of the
genes with the highest mean fold change of BRAFmutation were PSMC3IP, KIF3C, UBE2Q2,
SERPIND1 and PLAT, however only PLAT is displayed in Table 1. From the genes identified
through the two-stage algorithm, 35% of them encode proteins interacting with the BRAF
gene, though none of them directly. Most of the selected genes interact with the BRAF gene via
pathways mediated byHRAS,MAPK1 (ERK),MAP2K1 (MEK) and BAD (Fig 3A).
SinceHRASmutations are frequent in patients receiving BRAF targeted therapies [33], we
examined the mean estimated trajectory over different dosages under treatment with BRAF
inhibitors tested in six cancer cell lines with and without BRAF andHRASmutations (Fig 4).
As stated previously, we observed that in most cases HG6-64-1 seems to be the most effective
drug. The estimated coefficient functions facilitate drug examination and response prediction
under the different dosages. In some instances, we observed different drugs having similar
behaviour for lower drug dosages and larger divergence for higher dosages. In most cases,
regardless of the cell line origin, our method successfully estimates the expected survival rates
of the cancer cell lines for the different drugs given their gene expression information.
For validation purposes, we performed the same analysis using the independently-gener-
ated GDSC2 data set, with a different set of drugs. Note that the drug set in GDSC2 only par-
tially overlaps with the one used in GDSC1. The results are reported in supplementary S2 Fig,
and show similar properties to the analysis of the BRAF drugs in Fig 4. As the GDSC2 dose-
responses are produced from independently-generated experiments, the measured drug
PLOS COMPUTATIONAL BIOLOGY Biomarker detection for revealing anticancer drug dynamics
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Fig 2. Estimated coefficient functions for the low-dimensional predictors and three of the selected genes. Estimated coefficient functions for the
intercept, different drugs, tissue of origin and three of the selected genes along with 95% bootstrap confidence intervals. Baseline corresponds to BRAF
mutant cell lines treated with Dabrafenib in skin tumours.
https://doi.org/10.1371/journal.pcbi.1008066.g002
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response is different for some of the drug-cell line combinations. We observe some diver-
gences between GDSC1 and GDCS2 estimated trajectories for Dabrafenib and PLX-4720,
which can be explained due to measurement error in the GDSC experiments themselves.
Variable selection algorithm identifies cancer pathways associated with
BRAF inhibitor response
Using our functional regression approach, we identified 230 genes that were selected via the
SCAD step (observed gene set). We used the Enrichr [34, 35] andWikiPathways [36] databases
to see if the selected genes can be grouped into common functional classes or pathways. In
total, 183 were identified, of which 11 were statistically significant at 5% level, including apo-
ptosis modulation, NOTCH1 regulation, and MAPK signaling (S2 Table). The model identi-
fied genes (IKBKB, RASGRF1, DUSP16, DUSP8, DUSP6,MAPT and IL1R2) downstream of
the MAPK signaling pathway targeted by BRAF inhibitors.
Previous studies of these pathways have found associations with tumorigenesis and cancer
treatment [37–40]. Genes in more than one of these pathways include IKBKB, PLAT, IL1R2
and PDPK1. The IKB kinase composed of IKBKB had previously been suggested as a marker
of sensitivity for combination therapy with BRAF inhibitors [41]. Taken together, these results
suggest that the identified associations between the drug response and the observed genes may
reveal new predictive markers of tumour response to the examined BRAF inhibitors.
Fig 3. Protein-protein interaction network for the genes selected from the two-stage variable selection algorithm. (A) Undirected protein-protein interaction
network between the 230 selected (blue) and the BRAF (red) genes (full scale analysis). (B) Undirected protein-protein interaction network between the 65 genes
selected from the two-stage variable selection algorithm for the cell lines resistant to BRAF inhibitors (blue) and the BRAF (red) gene. In both panels genes depicted
with black are the interaction mediators. Commonmediators include theHRAS,MAPK1,MAP2K1 and BAD genes.
https://doi.org/10.1371/journal.pcbi.1008066.g003
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In addition to the pathway enrichment analysis, we used the Molecular Signatures Database
(MSigDB database v7.0 updated August 2019: [42]) to compute overlaps between the observed
gene set and known oncogenic gene sets. Fig 5A and S3 Table display the 29 overlaps found.
Interestingly, we identified three instances where the observed gene set significantly over-
lapped with gene sets over-expressing an oncogenic form of the KRAS gene.
We further explored potential biologically relevant pathways using the Reactome database
[44, 45]. More than 40 enriched pathways were identified at a 5% significance level. The top 40
pathways are depicted in Fig 6 along with the pathway-gene network of the top 5 pathways
(for the full list, see S4 Table). Interestingly, axon guidance and VEGF signalling were among
the enriched pathways, confirming relevance of the selected genes to the intended role of the
examined compounds, since BRAF kinase activity drives axon growth in the central nervous
system [46] and VEGF blockade has potential anti-tumour effects when combined with BRAF
inhibitors [47]. Note that axon growth has not, thus far, been directly implicated in BRAF
Fig 4. Estimated mean drug response trajectories for six cancer cell lines with BRAF andHRASmutations.Observed responses (points) and estimated mean
trajectory (lines) of cell concentration for cancer cell lines with and without BRAF andHRASmutations after treatment with the five anticancer compounds examined.
https://doi.org/10.1371/journal.pcbi.1008066.g004
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inhibitor activity, and, consequently, our analysis provides important evidence towards this
theory.
Identifying dose-dependent genes in drug-resistance conditions
Acquired resistance to BRAF inhibitors is often observed in the clinic [48]. To further examine
the utility of the employed methodology, we applied the variable selection algorithm to a data
subset containing only cell lines with mutations activating resistance mechanisms to BRAF
inhibitors [49]. Out of the 951 cell lines in the data, 191 had some mutation in any of the fol-
lowing: RAC1 gene, NRAS gene, cnaPANCAN44 or cnaPANCAN315. We identified 65 genes
Fig 5. Overlaps between the observed gene set and oncogenic signatures in the Molecular Signatures Database (full data analysis); signalling pathways
enriched for genes predictive of BRAF inhibitor response (resistant cell lines). (A) Full gene set names can be found in S3 Table. Overlaps have been
detected using gene set enrichment analysis performed using a hypergeometric distribution. The false discovery rate analog of the hypergeometric p-value is
displayed after correction for multiple hypothesis testing according to Benjamini and Hochberg [43]. (B) Top 20 enriched signalling pathways along with the
adjusted p-values and the number of overlapping genes obtained after pathway enrichment analysis to the resistant cell line analysis results (for the full list of
the pathways identified see S6 Table).
https://doi.org/10.1371/journal.pcbi.1008066.g005
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associated with dose-response, though none of them were directly associated with the MAPK/
ERK pathway. However, from these, 25 genes have been found to indirectly interact with the
BRAF gene (Fig 3B) and 21 to overlap with three oncogenic gene sets in the Molecular Signa-
tures Database (genes down-regulated in NCI-60 panel of cell lines with mutated TP53; genes
up-regulated in Sez-4 cells (T lymphocyte) that were first starved of IL2 and then stimulated
with IL21, and; genes down-regulated in mouse fibroblasts over-expressing E2F1 gene; S5
Table). Finally, we found 34 pathways enriched for genes predicting drug response of the
Fig 6. Pathway enrichment analysis using the Reactome database. (A) Top 40 enriched signalling pathways along with the adjusted p-values. For the full list, see S4
Table. (B) Pathway-gene network of the top 5 enriched signalling pathways as found using Reactome [44, 45].
https://doi.org/10.1371/journal.pcbi.1008066.g006
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mutated cell lines to the examined BRAF inhibitors, of which the top 20 are depicted in Fig 5B
(for the full list of the pathways identified see S6 Table).
Table 2 presents gene rankings based on the AUC and the overall coefficient function effect
(sign) for the 42 genes in either the enriched pathways, the three oncogenic gene sets discussed
above or the protein-protein interaction network with the BRAF gene (full list available in S7
Table). Eight of the selected genes in the current implementation were also selected from the
algorithm implemented on the full data: ASB9, PRSS33, GJA3, PLAT, KLF9, BFSP1,MTARC1
and UCN2.
Predictive performance of dose-dependent models
As discussed above, the employed methodology gives a good overview of the baseline genetic
effect on drug response. We assessed the overall predictive performance of our method using
10-fold cross validation under two different scenarios. For the first, we split the data into train-
ing and test set holding out the experimental units (cancer cell line-drug combinations) and
for the second, holding out cancer cell lines. The absolute mean error for both cases was
around 0.12. Our analysis showed robust cross-validated performance when it comes to pre-
dicting sensitivity to the administered drugs, as shown in S3 Fig which displays the correlation
between predicted and true response. This result was further validated by repeating the analy-
sis on the independently-generated GDSC2 data set, using a different set of drugs (S4 Fig),
which demonstrated comparable predictive performance.
Predictive accuracy for the dose-response curves was evaluated under four different sub-
scenarios: prediction of the most effective drug-dosage combination for the 951 cell lines in
the data set; prediction of the most effective drug given a cell line; prediction of the most effec-
tive dosage given treatment with a particular drug and prediction of the most effective dosage
range given treatment with a drug (Table 3). The proposed model performs well when it
comes to predicting the most effective drug or dosage range (�79% in both scenarios). Results
are less reliable when it comes to prediction of the exact dosage or drug-dosage combination
(�48-49% and�57-58% in both scenarios) but this can be due to either the large variability
observed in the observed responses or due to the small number of cell lines for some predictor
level combinations. Results were similar for both cross-validation scenarios (differences range
from 0 to<2%, Table 3), meaning that as long as a cell line has similar genetic characteristics
to those observed, the model can be reliable in predicting the outcome after anticancer drug
administration.
We additionally compared the performance of our two-stage algorithm approach to a
penalized linear (LASSO) regression for predicting the IC50 and area under the dose-
response curve (AUC). Note that our functional regression model is not directly predicting
either of these values, but rather predicts the full drug-response curve. As this is a harder
problem, we would expect the LASSO to have a natural advantage; however, our method has
the added benefit of being able to detect dose-dependent associations, which is not possible
when predicting summary statistics of the dose-response curve directly. We employed
10-fold cross-validation to evaluate the predictive error in terms of root mean squared error
(RMSE), and we used a sigmoid curve fit for estimating the IC50 values from the predicted
dose-response curves with our two-stage method. Our method outperformed standard
LASSO in terms of predicting the AUC (RMSE2−stage = 0.176; RMSELASSO = 0.347) and per-
formed well on predicting the IC50, although the LASSO performed better (RMSE2−stage =
1.969; RMSELASSO = 1.134). This could be expected, as estimating the IC50 from the pre-
dicted dose-response curve adds a further level of complexity, compared to directly predict-
ing this value using the LASSO.
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Table 2. Rankings of the genes identified from the pathway and oncogenic gene set enrichment analysis.
Gene Name Area SD Sign Spearman Correlation Mean fold change in BRAFmutant vs wild-type cell
lines
Protein-protein interaction network distance to
BRAF
MYO5A 0.531 0.261 + 0.955 1.358 4
S100A1 0.488 0.189 + 0.812 1.263 NI
GPNMB 0.424 0.196 + 1 1.169 3
ACP5 0.359 0.149 - -0.998 1.039 NI
FCGR2A 0.341 0.158 - -0.588 1.25 3
CITED1 0.28 0.348 0 -0.603 1.63 3
SPRY4 0.274 0.127 - -0.611 1.228 2
CD44 0.239 0.164 + 0.868 1.413 3
RAP2B 0.236 0.179 0 0.927 1.254 NI
KCNJ13 0.205 0.094 0 -0.604 1.101 3
ALX1 0.202 0.099 - -1 1.104 NI
PLAT 0.201 0.121 - -0.405 1.312 4
RETSAT 0.201 0.142 0 0.689 1.127 NI
GSN 0.196 0.109 + 0.588 1.079 4
CDH19 0.185 0.102 0 0.943 0.933 NI
ATP1B3 0.178 0.115 - -1 1.063 NI
BAZ1A 0.173 0.105 + -0.29 1.109 4
SLC16A4 0.166 0.117 - -0.298 1.234 NI
ST6GALNAC2 0.164 0.102 0 -0.815 1.264 NI
MFSD12 0.16 0.148 0 -0.788 1.13 NI
GJA3 0.157 0.075 0 -0.85 1.071 NI
CYP27A1 0.156 0.09 - -0.743 1.373 NI
EGLN1 0.15 0.119 - -0.442 1.053 3
TRPV2 0.147 0.118 0 0.769 1.074 NI
MITF 0.146 0.106 + 1 0.743 2
TBC1D7 0.146 0.118 0 -0.603 1.304 NI
SLC6A8 0.144 0.111 0 -0.263 0.941 NI
PTPRZ1 0.139 0.138 - -0.808 1.074 4
PLOD3 0.132 0.135 0 0.696 1.166 NI
ANKRD7 0.131 0.12 + 0.92 1.241 NI
KANK1 0.107 0.113 0 -0.493 1.345 NI
GYPC 0.105 0.092 + -0.3 1.072 NI
TYR 0.1 0.098 - 0.467 1.11 4
TYRP1 0.1 0.097 0 0.457 1.326 3
IGSF8 0.09 0.129 0 -0.668 1.313 5
SPRED1 0.067 0.116 0 -0.556 1.239 4
ITGA9 0.056 0.111 0 0.785 1.154 4
KREMEN1 0.053 0.086 0 -0.555 1.123 4
LAMA4 0.038 0.083 - 0.344 1.151 4
MLANA 0.037 0.097 0 0.534 1.147 NI
KLF9 0.011 0.074 0 0.932 1.064 NI
Table notes rankings of the genes found to have some biological importance. A positive (+) sign translates to a positive effect on cell survival after drug administration, a
negative (-) sign translates to a negative effect on cell survival and a neutral (0) effect translates to a varying effect on cell survival which depends on drug dosage.
Spearman correlation is calculated between drug dosage and gene estimated coefficient function values as an indicator of the magnitude change of the gene effect over
the increasing dosage. Area corresponds to the area under the estimated coefficient curve and the SD corresponds to the standard deviation of the area based on
bootstrapping. Pearson’s correlation is calculated between the selected gene microarray expression values and the BRAF expression across all the cell lines. Protein-
protein interaction network distance is computed based on the shortest interaction path between the BRAF gene and each of the selected genes. Here, NI denotes
absence of interaction.
https://doi.org/10.1371/journal.pcbi.1008066.t002
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Conclusion
Genetic alternations and gene expression in tumours are known to affect disease progression
and response to treatment. Here, we studied dosage-dependent associations between gene
expression and drug response, using a functional regression approach which adjusts for
genetic factors. We analysed data from the Genomics of Drug Sensitivity in Cancer project
relating to drug effectiveness for suspending cancer cell proliferation under different dosages,
and examined five BRAF targeted inhibitors, each applied in a number of common and rare
types of cancer cell lines. Our implementation of a two-stage screening algorithm revealed a
number of genes that are potentially associated with drug response. Gene, drug and cancer
type trajectories have been modeled using a varying coefficient modeling framework. The pro-
posed methodology allows for dose-dependent analysis of genetic associations with drug
response data. It enables us to study the effect of different drugs simultaneously, which results
in high accuracy of drug response prediction. Drug comparisons using the proposed method-
ology could support drug repositioning, especially in diseases where existing treatment options
are limited. In addition, our methodology can help to reveal unknown potential relationships
between genetic characteristics and drug efficacy. Hence, the good predictive performance of
our method could be due to the fact that some genes may act as proxies for unmeasured phe-
notypes that are directly relevant to drug sensitivity.
Our work relies on two major assumptions. First, that out of tens of thousands genes regu-
lating protein composition only a small proportion is actually associated with cancer cell sur-
vival in a dosage-dependent manner. In other words, transcriptomic profiles exert influence
on disease progress after drug administration in a sparse and dynamic way. However, if a large
number of genes is associated with the drug response, our method may produce biased results,
and some important information about the biological mechanisms can be lost. Secondly, we
assume that the different drugs are comparable on the scale of maximum dosage percentage
level for our joint model. We acknowledge that different drugs have different chemical struc-
ture and maximum screening concentrations. Our focus is to identify genetic components
that could be informative for dose response given drugs that belong to a particular family, for
example BRAF targeted therapies. However, our methodology is flexible enough to allow each
drug to be examined separately if it appears to be clinically appropriate.
Drug response prediction from gene expression data has been widely studied in the litera-
ture. Sparse regression methods, gene selection algorithms such as the Ping-pong algorithm
[50], or a combination of network analysis and penalized regression, e.g. the sparse network-
regularized partial least squares method [51], have all been employed to simultaneously predict
drug response and select genetic factors that seem to be associated with the drug response.
Table 3. Predictive performance of the employed model (mean absolute error = 0.121).
Scenario Accuracy EU Accuracy CL
Model predicts the more effective drug-dosage combination 57.85% 57.42%
Model predicts the more effective drug given a cell-line 78.21% 78.21%
Model predicts the more effective dosage given a drug 48.44% 48.65%
Model predicts the most effective dosage range (> or� 31.25% of the maximum
dosage)
79.47% 79.28%
Table notes the predictive performance of the model based on the percentages for correctly identifying the most
effective drug, dosage or drug-dosage combinations. Results obtained based on 10-fold cross-validation of the final
model (based on holding out either experimental units−EU− or cancer cell lines−CL−).
https://doi.org/10.1371/journal.pcbi.1008066.t003
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However, none of these methods are able to quantify the effect of drug dosage on the response,
which is one of the main contributions of this work. Employing the proposed dose-varying
model gives a detailed picture of different drug effects and can be extremely valuable in pre-
dicting drug response for agents with small therapeutic range and high toxicity levels. Our
algorithm showed moderate predictive performance due to the complexity of predicting whole
drug-response curves. Methods for further enhancing the performance of the proposed meth-
odology, such as judicious use of prior information and leveraging information sharing across
multiple data sources should be explored in the future in order to overcome this issue and
make good use of its full potentials.
To conclude, the main purpose of this paper is to examine the dose-dependent associations
between genes and drugs. The proposed methodology, by using the raw data to infer the effects
of interest, allows to obtain a more comprehensive picture of the biological mechanisms that
undergo cancer treatment and the role of drug dose on that. In addition, due to its simple
structure, it allows extension to different types of molecular data (e.g. RNA-seq gene expres-
sion, methylation or mutational profiles) and enrichment with further information, such as
drug chemical composition.
Supporting information
S1 Text. Accurate detection of drug associated genes from simulated responses. Simulated
responses have been generated to examine the accuracy of the employed method in detecting
the genes that are truly associated to drug response. Three screening thresholds, three active
gene sets and two covariance structure scenarios for the repeated measurements simulation
have been considered. This text includes all the details of the simulation study that we con-
ducted.
(PDF)
S1 Fig. Distribution of tissue of origin across the five BRAF compounds used for cell line
screening in the Genomics of Drug Sensitivity in Cancer data.Overall, similar proportion of
cell lines have been treated with all of the compounds examined with smaller number of cell
lines been treated with AZ628, Dabrafenib and PLX-4720. Larger number of cell lines in the
data set were originated from the lungs, the gastrointestinal tract and the haematopoietic and
lymphoid tissues.
(TIF)
S2 Fig. Estimated mean drug response trajectories for BRAF andHRASmutated and non-
mutated cancer cell lines: analysis performed on GDSC2 data.Observed responses (points)
and estimated mean trajectory (lines) of cell concentration for cancer cell lines with and with-
out BRAF andHRASmutations after treatment with the eight anticancer compounds exam-
ined using data from GDSC2.
(TIF)
S3 Fig. Prediction accuracy for each different drug and scenario. Pearson correlation was
estimated across observed and predicted AUC values. AUC values have been computed by cal-
culating the area under the coefficient function curve (both observed and predicted). Training
and test sets have been considered based on either the experimental units or on cancer cell
lines only.
(TIF)
S4 Fig. Prediction accuracy for each different drug and scenario: analysis performed on
GDSC2 data. Pearson correlation across observed and predicted AUC values. AUC values
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have been computed by calculating the area under the coefficient function curve (both
observed and predicted) using the GDSC2 data. Training and test sets have been considered
based on either the experimental units or on cancer cell lines only.
(TIF)
S1 Table. Full gene rankings based on the estimated area under the coefficient function
curve (analysis on the full data set).Gene rankings of all selected genes based on the magni-
tude of the genetic effect on drug response. A positive (+) sign translates to a positive effect on
cells survival after drug administration, a negative (-) sign translates to a negative effect on
cells survival and a mixed (0) effect translates to a varying effect on cells survival which
depends on drug dosage. Spearman’s correlation is calculated between drug dosage and gene
estimated coefficient function values as an indicator of the magnitude change of the gene effect
over the increasing dosage. Area corresponds to the area under the estimated coefficient curve
and the SD corresponds to the standard deviation of the area based on bootstrapping. Mean
fold change is calculated between the selected gene expression values of the cell lines carrying
BRAF mutations with respect to wild type. Protein-protein interaction network distance is
computed based on the shortest interaction path between the BRAF gene and each of the
selected genes. Here, NI denotes absence of any interaction.
(XLSX)
S2 Table. Signalling pathways linked to genes predictive of BRAF inhibitor response (anal-
ysis on the full data set). Signalling pathways along with the adjusted p-values and the num-
ber of overlapping genes obtained after pathway enrichment analysis applied to the full scale
analysis results.
(XLSX)
S3 Table. Overlaps between the observed gene set and oncogenic signatures in the Molecu-
lar Signatures database (analysis on the full data set).Overlaps have been detected using
gene set enrichment analysis performed using a hypergeometric distribution. The false discov-
ery rate analog of the hypergeometric p-value is displayed after correction for multiple hypoth-
esis testing according to Benjamini and Hochberg.
(XLSX)
S4 Table. Signalling pathways linked to genes predictive of BRAF inhibitor response (anal-
ysis on the full data set)-Reactome. Signalling pathways along with the adjusted p-values and
the number of overlapping genes obtained after pathway enrichment analysis applied to the
full scale analysis results using the Reactome database.
(XLSX)
S5 Table. Overlaps between the observed gene set and oncogenic signatures in the Molecu-
lar Signatures database (resistant cell lines analysis).Overlaps have been detected using
gene set enrichment analysis performed using a hypergeometric distribution. The false discov-
ery rate analog of the hypergeometric p-value is displayed after correction for multiple hypoth-
esis testing according to Benjamini and Hochberg.
(XLSX)
S6 Table. Signalling pathways linked to genes predictive of BRAF inhibitor response (anal-
ysis on resistant cell lines). Signalling pathways along with the adjusted p-values and the
number of overlapping genes obtained after pathway enrichment analysis applied to the resis-
tant cell line analysis results.
(XLSX)
PLOS COMPUTATIONAL BIOLOGY Biomarker detection for revealing anticancer drug dynamics
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1008066 January 25, 2021 21 / 25
S7 Table. Full gene rankings based on the estimated area under the coefficient function
curve (analysis on resistant cell lines). Gene rankings of all selected genes based on the mag-
nitude of the genetic effect on drug response. A positive (+) sign translates to a positive effect
on cells survival after drug administration, a negative (-) sign translates to a negative effect
on cells survival and a mixed (0) effect translates to a varying effect on cells survival which
depends on drug dosage. Spearman’s correlation is calculated between drug dosage and gene
estimated coefficient function values as an indicator of the magnitude change of the gene effect
over the increasing dosage. Area corresponds to the area under the estimated coefficient curve
and the SD corresponds to the standard deviation of the area based on bootstrapping. Mean
fold change is calculated between the selected gene expression values of the cell lines carrying
BRAFmutations with respect to wild type. Protein-protein interaction network distance is
computed based on the shortest interaction path between the BRAF gene and each of the
selected genes. Here, NI denotes absence of any interaction.
(XLSX)
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